Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)

NCT05059262 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.

NCT NCT05059262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Lead sponsor
Deciphera Pharmaceuticals, LLC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 14, 2021
Completion date
July 31, 2028
Enrollment
123 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell tumor of tendon sheath, pigmented villonodular synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse, tenosynovial giant cell tumor, localized